Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs Market By Type (Afinitor (Everolimus), Avastin (Bevacizumab), Cabomety (Cabozantinib), Inlyta (Axitinib), Nexavar (Sorafenib), Proleukin (Aldesleukin), Torisel (Temsirolimus), Sutent (Sunitinib), Votrient (Pazopanib)) - Growth, Future Prospects, And Competitive Analysis, 2017 -2025

Kidney cancer is the most common cancer in the world around 63,990 new cases are estimated to be in 2017. Among the primary kidney cancer, renal parenchymal cancer is the most common estimating around 80-90% and it is the most complex to treat. The chances of developing cancer is about 1 in 63 in lifetime, with higher risk in men than women. There is rise in the incidences of renal cell carcinoma in recent decade, due to unhealthy lifestyle such as smoking, obesity and decline in physical activity. Thus, with increase in aged population and growth in incidences of kidney cancer and drugs in pipeline for approval would drive the growth of kidney cancer drug market.

The report titled “Kidney Cancer/Renal Cell Carcinoma Drugs Market - Growth, Future Prospects and Competitive Analysis, 2017–2025” offers strategic insights into the overall kidney cancer drugs market along with the market size and estimates for the duration 2015 to 2025. The said research study covers in-depth analysis of multiple market segments based on type of drug and different geographies.

Geographically, the global kidney cancer/ renal cell carcinoma drugs market is studied for the following regional markets:

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • GCC
  • Rest of Middle East and Africa

Market size and forecast for these regional and country level markets are presented in this study for the period 2015-2025. Market growth rates for the forecast period 2017-2025 are also included in this report, considering 2016 as the base year. Further cross-sectional presented in terms of drug and constituent region/country level markets is also included in this section.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global kidney cancer drugs market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global kidney cancer/renal cell cancer drugs market. This report concludes with company profiles section that highlights major information about the key players engaged in global kidney cancer/renal cell carcinoma drugs market. In-depth competitive environment analysis and historical (2015) market size data are also provided in the report.

Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the vascular grafts market. The key players profiled in this report are Active Biotech Ab, Amgen, Bayer AG, Cipla Limited, F. Hoffmann-La Roche Ag, Genentech, Inc., GlaxoSmithKline Plc, Novartis AG, Onyx, Pfizer, Inc. and others.

Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase II-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global Kidney Cancer Drugs Market Portraiture
2.1.1. Global Kidney Cancer Drugs Market, by Drug Type, 2016
2.1.2. Global Kidney Cancer Drugs Market, by Geography, 2016

Chapter 3. Kidney Cancer Drugs: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Epidemiology of Kidney Cancer
3.3. Drivers
3.4. Challenges
3.5. Opportunities
3.5.1. Attractive Investment Proposition, by Geography
3.6. Competitive Landscape
3.6.1. Competitive Landscape, by Key Players, 2016

Chapter 4. Global Kidney Cancer Drugs Market, by Type, 2015 – 2025 (US$ Mn)
4.1. Overview
4.2. Attractive Investment Proposition: Global Kidney Cancer Drugs Market, by Type
4.3. Afinitor (Everolimus)
4.4. Avastin (Bevacizumab)
4.5. Cabomety (Cabozantinib)
4.6. Inlyta (Axitinib)
4.7. Nexavar (Sorafenib)
4.8. Proleukin (Aldesleukin)
4.9. Torisel (Temsirolimus)
4.10. Sutent (Sunitinib)
4.11. Votrient (Pazopanib)

Chapter 5. Global Kidney Cancer Drugs Market: Pipeline Analysis
5.1. Overview
5.1.1. Phase III (Market estimations by 2025)
5.1.1.1. Tivozanib
5.1.2. Phase II (Qualitative Information)
5.1.3. Phase I (Qualitative Information)
5.1.4. Preclinical Studies (Qualitative Information)

Chapter 6. Global Kidney Cancer Drugs Market, by Geography, 2015 – 2025 (US$ Mn)
6.1. Overview
6.2. North America Kidney Cancer Drugs Market Analysis, 2015 – 2025
6.2.1. North America Kidney Cancer Drugs Market, by Drugs Type, 2015 – 2025 (US$ Mn)
6.2.2. North America Kidney Cancer Drugs Market, by Country, 2015 – 2025 (US$ Mn)
6.2.2.1. U.S.
6.2.2.1.1. U.S. Kidney Cancer Drugs Market, by Drugs Type, 2015 – 2025 (US$ Mn)
6.2.2.2. Canada
6.2.2.2.1. Canada Kidney Cancer Drugs Market, by Drugs Type, 2015 – 2025 (US$ Mn)
6.3. Europe Kidney Cancer Drugs Market Analysis, 2015 – 2025
6.3.1. Europe Kidney Cancer Drugs Market, by Drugs Type, 2015 – 2025 (US$ Mn)
6.3.2. Europe Kidney Cancer Drugs Market, by Treatment Type, 2015 – 2025 (US$ Mn)
6.3.3. Europe Kidney Cancer Drugs Market, by Country, 2015 – 2025 (US$ Mn)
6.3.3.1. U.K.
6.3.3.1.1. U.K. Kidney Cancer Drugs Market, by Drugs Type, 2015 – 2025 (US$ Mn)
6.3.3.2. Germany
6.3.3.2.1. Germany Kidney Cancer Drugs Market, by Drugs Type, 2015 – 2025 (US$ Mn)
6.3.3.3. Rest of Europe
6.3.3.3.1. Rest of Europe Kidney Cancer Drugs Market, by Drugs Type, 2015 – 2025 (US$ Mn)
6.4. Asia Pacific Kidney Cancer Drugs Market Analysis, 2015 – 2025
6.4.1. Asia Pacific Kidney Cancer Drugs Market, by Drugs Type, 2015 – 2025 (US$ Mn)
6.4.2. Asia Pacific Kidney Cancer Drugs Market, by Country, 2015 – 2025 (US$ Mn)
6.4.2.1. Japan
6.4.2.1.1. Japan Kidney Cancer Drugs Market, by Drugs Type, 2015 – 2025 (US$ Mn)
6.4.2.2. China
6.4.2.2.1. China Kidney Cancer Drugs Market, by Drugs Type, 2015 – 2025 (US$ Mn)
6.4.2.3. Rest of Asia Pacific
6.4.2.3.1. Rest of Asia Pacific Kidney Cancer Drugs Market, by Drugs Type, 2015 – 2025 (US$ Mn)
6.5. Latin America Kidney Cancer Drugs Market Analysis, 2015 – 2025
6.5.1. Latin America Kidney Cancer Drugs Market, by Drugs Type, 2015 – 2025 (US$ Mn)
6.5.2. Latin America Kidney Cancer Drugs Market, by Country, 2015 – 2025 (US$ Mn)
6.5.2.1. Brazil
6.5.2.1.1. Brazil Kidney Cancer Drugs Market, by Drugs Type, 2015 – 2025 (US$ Mn)
6.5.2.2. Mexico
6.5.2.2.1. Mexico Kidney Cancer Drugs Market, by Drugs Type, 2015 – 2025 (US$ Mn)
6.5.2.3. Rest of Latin America
6.5.2.3.1. Rest of Latin America Kidney Cancer Drugs Market, by Drugs Type, 2015 – 2025 (US$ Mn)
6.6. Middle East & Africa (MEA) Kidney Cancer Drugs Market Analysis, 2015 – 2025
6.6.1. MEA Kidney Cancer Drugs Market, by Drugs Type, 2015 – 2025 (US$ Mn)
6.6.2. MEA Kidney Cancer Drugs Market, by Region, 2015 – 2025 (US$ Mn)
6.6.2.1. GCC
6.6.2.1.1. GCC Kidney Cancer Drugs Market, by Drugs Type, 2015 – 2025 (US$ Mn)
6.6.2.2. Rest of MEA
6.6.2.2.1. Rest of MEA Kidney Cancer Drugs Market, by Drugs Type, 2015 – 2025 (US$ Mn)

Chapter 7. Company Profiles
7.1. Active Biotech Ab
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product/Service Portfolio
7.1.4. Key Developments
7.2. Amgen
7.3. Bayer AG
7.4. Cipla Limited
7.5. F. Hoffmann-La Roche Ag
7.6. Genentech, Inc.
7.7. Glaxosmithkline Plc
7.8. Novartis Ag
7.9. Onyx
7.10. Pfizer, Inc.
7.11. Other Notable Players 

List Of Table :

TABLE 1 Global Kidney Cancer Drugs Market, by Drugs Type, 2015 – 2025 (US$ Mn)
TABLE 2 North America Kidney Cancer Drugs Market, by Drugs Type, 2015 – 2025 (US$ Mn)
TABLE 3 North America Kidney Cancer Drugs Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 4 Europe Kidney Cancer Drugs Market, by Drugs Type, 2015 – 2025 (US$ Mn)
TABLE 5 Europe Kidney Cancer Drugs Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 6 Asia Pacific Kidney Cancer Drugs Market, by Drugs Type, 2015 – 2025 (US$ Mn)
TABLE 7 Asia Pacific Kidney Cancer Drugs Market, by Country, 2015 – 2025(US$ Mn)
TABLE 8 Latin America Kidney Cancer Drugs Market, by Drugs Type, 2015 – 2025(US$ Mn)
TABLE 9 Latin America Kidney Cancer Drugs Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 10 Middle East and Africa Kidney Cancer Drugs Market, by Drugs Type, 2015 – 2025 (US$ Mn)
TABLE 11 Middle East and Africa Kidney Cancer Drugs Market, by Region, 2015 – 2025 (US$ Mn)
TABLE 12 Active Biotech Ab: Company Snapshot (Business Description, Financial Information, Product/Service Portfolio, Key Developments)
TABLE 13 Amgen: Company Snapshot (Business Description, Financial Information, Product/Service Portfolio, Key Developments)
TABLE 14 Bayer AG: Company Snapshot (Business Description, Financial Information, Product/Service Portfolio, Key Developments)
TABLE 15 Cipla Limited: Company Snapshot (Business Description, Financial Information, Product/Service Portfolio, Key Developments)
TABLE 16 F. Hoffmann-La Roche Ag: Company Snapshot (Business Description, Financial Information, Product/Service Portfolio, Key Developments)
TABLE 17 Genetech, Inc.: Company Snapshot (Business Description, Financial Information, Product/Service Portfolio, Key Developments)
TABLE 18 Glaxosmithkline Plc: Company Snapshot (Business Description, Financial Information, Product/Service Portfolio, Key Developments)
TABLE 19 Novartis Ag: Company Snapshot (Business Description, Financial Information, Product/Service Portfolio, Key Developments)
TABLE 20 Onyx: Company Snapshot (Business Description, Financial Information, Product/Service Portfolio, Key Developments)
TABLE 21 Pfizer,Inc.: Company Snapshot (Business Description, Financial Information, Product/Service Portfolio, Key Developments)

List Of Figure :

FIG. 1 Kidney Cancer Drugs : Market Segmentation
FIG. 2 Global Kidney Cancer Drugs Market Share, by Drugs Type, 2016 (US$ Mn)
FIG. 3 Global Kidney Cancer Drugs Market, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition, by Geography
FIG. 5 Market Competition Landscape, by Key Players, 2016
FIG. 6 Global Sutent (Sunitinib)Kidney Cancer Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 7 Global Nexavar (Sorafenib)Kidney Cancer Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 8 Global Afinitor (Everolimus)Kidney Cancer Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 9 Global Votrient (Pazopanib)Kidney Cancer Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 10 Global Inlyta (Axitinib) Kidney Cancer Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 11 Global Avastin (Bevacizumab) Kidney Cancer Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 12 Global Torisel (Temsirolimus) Kidney Cancer Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 13 Global Proleukin (Aldesleukin) Kidney Cancer Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 14 U.S. Kidney Cancer Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 15 Canada Kidney Cancer Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 16 U.K. Kidney Cancer Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 17 Germany Kidney Cancer Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 18 Rest of Europe Kidney Cancer Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 19 Japan Kidney Cancer Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 20 China Kidney Cancer Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 21 Rest of Asia Pacific Kidney Cancer Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 22 Brazil Kidney Cancer Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 23 Mexico Kidney Cancer Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 24 Rest of Latin America Kidney Cancer Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 25 GCC Kidney Cancer Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 26 Rest of Middle East and Africa Kidney Cancer Drugs Market, 2015 – 2025 (US$ Mn)

Based on the type of drugs, the global kidney cancer drugs market is segmented as follows:

• Sutent (Sunitinib)
• Nexavar (Sorafenib)
• Afinitor (Everolimus)
• Votrient (Pazopanib)
• Inlyta (Axitinib)
• Avastin (Bevacizumab)
• Torisel (Temsirolimus)
• Proleukin (Aldesleukin)

Renal cell carcinoma is the most common type of cancer observed in developed countries. Surgical treatment do not suffice at times and need other additional treatments.  Most promising treatment is target therapies that are commonly used for of kidney cancer. Sutent, Nexavar, Votrient are commonly used drugs for renal cell carcinoma treatment. Sutent occupies the largest share, thus dominating the kidney cancer drugs market. It is most commonly prescribed first line treatment drug for renal cell carcinoma. Votrient is anticipated to be the fast growing market in the forecast period. With patent expiry of branded drugs, entry of generics would affect the kidney cancer drugs market negatively. However, novel drugs in phase 2 and 3 of clinical trials would further propel the growth of kidney cancer drugs market.

For the purpose of this study, the global kidney cancer drugs market is geographically categorized into:

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • France
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • Rest of Asia
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East and Africa
  • GCC
  • Rest of Middle East and Africa

In 2016, North America occupies the major share of kidney cancer drugs market followed by Europe. North America and Europe have the highest incidences of kidney cancer and lowest is found in Africa and Asia. It is observed that kidney cancer is more prevalent in developed region around 59%. In U.S. around 65,000 new cases are diagnosed each year and 13,500 deaths occur due to renal cell carcinoma annually. It is the seventh most common cancer in men and the ninth most common in women. Rise in incidences of kidney cancer, well established healthcare infrastructure and favorable reimbursement policies are some of the key reasons for growth of kidney cancer/renal cell carcinoma drugs market in North America. Asia Pacific is the fastest growing kidney cancer/renal cell carcinoma drugs market. Rising geriatric population, improvement in overall healthcare infrastructure, increase in patient awareness availability of generics and improved diagnostic technology are the key reason for the growth of lucrative Asia Pacific market.